early reduction of serum-free light chains associates with renal recovery in myeloma kidney
DESCRIPTION
Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney. Sophina Hissaund FY2. Aims. Myeloma The Study Treatment Results Survival Conclusion Discussion. Myeloma. Malignant clonal proliferation of B-lymphocyte derived plasma cells - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/1.jpg)
Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney
Sophina HissaundFY2
![Page 2: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/2.jpg)
Aims
• Myeloma• The Study• Treatment• Results• Survival• Conclusion• Discussion
![Page 3: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/3.jpg)
Myeloma
• Malignant clonal proliferation of B-lymphocyte derived plasma cells
• A single clone of plasma cells produce identical immunoglobulins seen as a monoclonal band, or paraprotein, on serum or urine electrophoresis
![Page 4: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/4.jpg)
Myeloma Kidney
• Myeloma kidney can cause severe irreversible renal failure in patients with multiple myeloma
• The tubulointerstitial injury is a consequence of high concentrations of circulating monoclonal FLCs produced by a clonal expansion of plasma cells
![Page 5: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/5.jpg)
The Study• To determine the relationship between the achieved early FLC
reduction and renal recovery
• University Hospital Birmingham and Mayo Clinic, Rochester, Minnesota
• 39 patients
• 23 male, 16 female
• Median age 62 years
![Page 6: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/6.jpg)
The Study
• Severe renal failure at presentation
• Biopsy proven myeloma kidney
• 79% first presentation of myeloma
• 15% MGUS before diagnosis
• 24 patients required dialysis support
![Page 7: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/7.jpg)
![Page 8: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/8.jpg)
Treatment
• Birmingham – combination of extended haemodialysis with
thalidomide-based chemotherapy for patients with new presentation of myeloma
– Bortezomib for relapsing disease
![Page 9: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/9.jpg)
Treatment
• Minnesota– Plasma exchange in combination with
chemotherapy regimen consisting of high dose steroids used alone or with Bortezomib, thalidomide, melphalan, vincristine, doxorubicin or alemtuzumab
![Page 10: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/10.jpg)
![Page 11: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/11.jpg)
Results
Day 12 – each increment of 10% FLC reduction was associated with a 60% increase in likelihood of renal recovery
![Page 12: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/12.jpg)
Results
Day 21 –an additional 10% FLC reduction was associated with 60% increased likelihood of recovery
![Page 13: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/13.jpg)
![Page 14: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/14.jpg)
The relationship of reduction in serum FLCs and renal recovery is linear in patients with myeloma kidney
Results
![Page 15: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/15.jpg)
Long Term Survival Outcomes
• Median survival of patients who recovered renal function was 42.7 months
• Risk of death 3x lower for patients with a new myeloma and those with renal recovery
• Patients with λ FLCs had a significant higher likelihood of death
![Page 16: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/16.jpg)
Long Term Survival Outcomes
No significant association between % reduction of serum FLC concentration and survival
![Page 17: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/17.jpg)
Conclusion
• No absolute threshold by which FLCs must be reduced to facilitate renal recovery
• To enable a renal recovery rate of 80%, a 60% reduction in FLC levels by day 21 is required
• Targeting treatment to reverse renal failure in myeloma kidney by early reduction of FLCs is critical
![Page 18: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/18.jpg)
Discussion
• Combination
• Plasma exchange
• Biopsy results
• Pre –existing renal disease
• Small study
![Page 19: Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney](https://reader035.vdocument.in/reader035/viewer/2022062410/56816449550346895dd6111f/html5/thumbnails/19.jpg)
Thank you